Trial Profile
Obinutuzumab Containing Conditioning Regimen for CLL Patients and Patients With Richter's Transformation Requiring an Allogeneic Stem Cell Transplantation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia; Richter's syndrome
- Focus Adverse reactions; Therapeutic Use
- Acronyms CLLTX1
- 10 Oct 2019 Status changed from active, no longer recruiting to discontinued.
- 05 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 02 Jun 2017 Status changed from not yet recruiting to recruiting.